In the Phase I dose escalation portion, which evaluated the combination in participants with small cell lung cancer, the first patient treated attained partial remission.
Vivacity-MG3 Trial Confirms Nipocalimab’s Efficacy, Safety in Treating Generalized Myasthenia Gravis
Phase III Vivacity-MG3 trial shows that nipocalimab, an investigational FcRn blocker, significantly the improves symptoms of generalized myasthenia gravis with a manageable safety profile.
In this video interview, Dipanwita Das, CEO & co-founder at Sorcero, looks back to 2024 and discusses some of the industry’s ...
End-to-end offering is designed to streamline site activation and optimize visibility in critical research processes.
Use of decentralized approach in a Phase 1 pharmacokinetic trial shows the ability to enable remote data collection and ...
In this video interview, Dipanwita Das, CEO & co-founder at Sorcero, highlights how artificial intelligence, real-time monitoring, and historical data can aid in optimizing trial design.
“The goal is to develop life-saving medications for patients faster. That comes down to saving time and money,” said Bonne ...
Investigators find that most exclusion criteria in critical care randomized clinical trials are justifiable, but 60% include ...
In this video interview, Dipanwita Das, CEO & co-founder at Sorcero, discusses challenges such as high costs and long ...
Initiatives to Establish Capabilities in Early Phase Clinical Research in Malaysia ...
Initiatives to Establish Capabilities in Early Phase Clinical Research in Malaysia ...
Phase III HELIOS-B trial found that Amvuttra (vutrisiran) also preserved functional capacity and quality of life in patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback